{"id":"3d697228-c647-53a2-a7fb-3e5a72b4c57f","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:the-same-cohort-reports-no-effect-at-the-lower-dose","predicate":"does_not_change","statement":"The same cohort found nattokinase ineffective for lipids and atherosclerosis progression at 3,600 FU per day.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"652a6523-7b8b-52a3-b154-e29a31b6efc4","mechanism_event_label":"The same cohort found nattokinase ineffective for lipids and atherosclerosis progression at 3,600 FU per day.","subject":{"id":"e8eb9bb4-3c6f-5e96-a968-a6d1fece71e7","slug":"nattokinase-supplement","display_name":"Commercial nattokinase supplement, composition study-specific","entity_type_key":"chemical_species"},"object":{"id":"38b5e553-7784-5ea9-8bca-c48dd5075f74","slug":"carotid-intima-media-thickness","display_name":"Carotid artery intima-media thickness","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"652a6523-7b8b-52a3-b154-e29a31b6efc4","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:the-same-cohort-reports-no-effect-at-the-lower-dose-event","event_type":"observed_intervention","label":"The same cohort found nattokinase ineffective for lipids and atherosclerosis progression at 3,600 FU per day.","description":"Carotid artery imaging and blood lipids","status":"provisional","compartment":null,"participants":[{"entity":{"id":"e8eb9bb4-3c6f-5e96-a968-a6d1fece71e7","slug":"nattokinase-supplement","display_name":"Commercial nattokinase supplement, composition study-specific","entity_type_key":"chemical_species"},"role":"acting component","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"38b5e553-7784-5ea9-8bca-c48dd5075f74","slug":"carotid-intima-media-thickness","display_name":"Carotid artery intima-media thickness","entity_type_key":"cellular_process"},"role":"component the finding is about","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"12 months","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human (1,062 outpatients)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Nattokinase, 3,600 FU per day","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Same design limitations. Recorded because it is the only dose-comparison in the chapter and because it sits directly against the three-year randomized null at 2,000 FU per day. PubMed links an erratum to this article.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Human (1,062 outpatients)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The same cohort found nattokinase ineffective for lipids and atherosclerosis progression at 3,600 FU per day.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. (2022) https://pubmed.ncbi.nlm.nih.gov/36072877/ DOI: 10.3389/fcvm.2022.964977 Correction on record: Erratum in: Front Cardiovasc Med. 2022 Dec 05;9:1076420. doi: 10.3389/fcvm.2022.1076420. PMID 36545015.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vivo, oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Carotid artery imaging and blood lipids","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"f0562aaf-646f-5e33-a60b-9bc7d9ec5c93","evidence_kind":"source_excerpt","locator":"Lines 1159-1159","start_line":1159,"end_line":1159,"excerpt":"The same cohort found nattokinase ineffective for lipids and atherosclerosis progression at 3,600 FU per day.","model_system":"Human (1,062 outpatients)","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"41cb127c-1c23-53aa-b7d0-5ec7f6fa3c99","stable_key":"import-33bef151-bdc7-5892-aff6-0345ab149739","title":"Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23)","document_type":"imported_text","citation_label":"Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text.","file_path":"","sha256":"34fc46e0e849d06bfa13cb099a79b50679dd6fd0de8a5a0575326afdde3259c1","revision_id":"efd063e6-e982-5f6e-a4b8-6f2ffe4185ce","review_status":"unverified_draft","notes":""}}],"relations":[{"id":"aead9f9d-2906-5f37-bba3-21b1a844a757","relation_type":"qualifies","notes":"The same cohort reporting nothing at 3,600 FU per day is what makes the 10,800 FU result a dose-response argument rather than only an uncontrolled one.","source_claim_id":"3d697228-c647-53a2-a7fb-3e5a72b4c57f","source_claim_key":"33bef151-bdc7-5892-aff6-0345ab149739:the-same-cohort-reports-no-effect-at-the-lower-dose","source_statement":"The same cohort found nattokinase ineffective for lipids and atherosclerosis progression at 3,600 FU per day.","target_claim_id":"7c5092e7-475a-58ca-9738-90ac955f6222","target_claim_key":"33bef151-bdc7-5892-aff6-0345ab149739:a-retrospective-cohort-reports-plaque-reduction-at-high-dose","target_statement":"In a retrospective cohort of 1,062 participants, 10,800 FU per day for 12 months was followed by reduced carotid intima-media thickness and carotid plaque size, with improvement rates of 66.5 to 95.4%."}],"conflicts":[],"corrections":[],"research":null}